BACKGROUND: A doctor's diagnosis of asthma is associated with increased morbidity (pain and acute chest syndrome [ACS]) among children with sickle cell disease (SCD). An association between IgE levels and asthma and morbidity has not been investigated in children with SCD. OBJECTIVE: We tested the hypothesis that elevated total and allergen-specific IgE levels are associated with asthma and SCD morbidity in children with SCD. METHODS: A cross-sectional study of children with SCD who participated in the Silent Cerebral Infarct Trial was conducted. Logistic regression and negative binomial regression were used to investigate potential associations of total and allergen-specific IgE levels with asthma diagnosis and SCD morbidity, both confirmed by medical record review. Elevation of total IgE level was defined as age-adjusted and sex-adjusted IgE level exceeding the 90th percentile compared with a nonatopic reference population. IgE antibody positivity to Alternaria alternata (mold), Blattellagermanica (cockroach), and Dermatophagoides pteronyssinus (dust mite) was assessed by ImmunoCAP analysis. RESULTS: Children with SCD (140 with asthma; 381 without asthma) were evaluated. Elevations in total IgE level (P = .04) and IgE antibody specific for Alternaria alternata (P = .0003), Blattella germanica (P = .008), and Dermatophagoides pteronyssinus (P = .01) were associated with asthma. ACS (P = .048) but not pain (P = .20) was associated with total IgE level, but neither was associated with specific IgE levels. CONCLUSION: Significantly increased levels of total and allergen-specific IgE levels are associated with asthma in SCD. High IgE levels are a risk factor for ACS but not pain rates.
BACKGROUND: A doctor's diagnosis of asthma is associated with increased morbidity (pain and acute chest syndrome [ACS]) among children with sickle cell disease (SCD). An association between IgE levels and asthma and morbidity has not been investigated in children with SCD. OBJECTIVE: We tested the hypothesis that elevated total and allergen-specific IgE levels are associated with asthma and SCD morbidity in children with SCD. METHODS: A cross-sectional study of children with SCD who participated in the Silent Cerebral Infarct Trial was conducted. Logistic regression and negative binomial regression were used to investigate potential associations of total and allergen-specific IgE levels with asthma diagnosis and SCD morbidity, both confirmed by medical record review. Elevation of total IgE level was defined as age-adjusted and sex-adjusted IgE level exceeding the 90th percentile compared with a nonatopic reference population. IgE antibody positivity to Alternaria alternata (mold), Blattellagermanica (cockroach), and Dermatophagoides pteronyssinus (dust mite) was assessed by ImmunoCAP analysis. RESULTS:Children with SCD (140 with asthma; 381 without asthma) were evaluated. Elevations in total IgE level (P = .04) and IgE antibody specific for Alternaria alternata (P = .0003), Blattella germanica (P = .008), and Dermatophagoides pteronyssinus (P = .01) were associated with asthma. ACS (P = .048) but not pain (P = .20) was associated with total IgE level, but neither was associated with specific IgE levels. CONCLUSION: Significantly increased levels of total and allergen-specific IgE levels are associated with asthma in SCD. High IgE levels are a risk factor for ACS but not pain rates.
Authors: X Wang; D Wypij; D R Gold; F E Speizer; J H Ware; B G Ferris; D W Dockery Journal: Am J Respir Crit Care Med Date: 1994-06 Impact factor: 21.405
Authors: Karl P Sylvester; Richard A Patey; Simon Broughton; Gerrard F Rafferty; David Rees; Swee Lay Thein; Anne Greenough Journal: Pediatr Pulmonol Date: 2007-02
Authors: E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci Journal: N Engl J Med Date: 2000-06-22 Impact factor: 91.245
Authors: Kirkwood A Pritchard; Thom R Feroah; Sandhya D Nandedkar; Sandra L Holzhauer; William Hutchins; Marie L Schulte; Robert C Strunk; Michael R Debaun; Cheryl A Hillery Journal: Am J Respir Cell Mol Biol Date: 2011-10-27 Impact factor: 6.914
Authors: Shaina M Willen; Mark Rodeghier; Robert C Strunk; Leonard B Bacharier; Carol L Rosen; Fenella J Kirkham; Michael R DeBaun; Robyn T Cohen Journal: Br J Haematol Date: 2018-01-24 Impact factor: 6.998
Authors: Christopher J Bean; Sheree L Boulet; Genyan Yang; Amanda B Payne; Nafisa Ghaji; Meredith E Pyle; W Craig Hooper; Pallav Bhatnagar; Jeffrey Keefer; Emily A Barron-Casella; James F Casella; Michael R Debaun Journal: Br J Haematol Date: 2013-08-16 Impact factor: 6.998
Authors: Robyn T Cohen; Mark Rodeghier; Fenella J Kirkham; Carol L Rosen; Jane Kirkby; Michael R DeBaun; Robert C Strunk Journal: J Allergy Clin Immunol Date: 2016-08-09 Impact factor: 10.793
Authors: Pallav Bhatnagar; Jeffrey R Keefer; James F Casella; Emily A Barron-Casella; Christopher J Bean; Craig W Hooper; Amanda B Payne; Dan E Arking; Michael R Debaun Journal: Pediatr Blood Cancer Date: 2013-05-15 Impact factor: 3.167
Authors: Christopher J Bean; Sheree L Boulet; Dorothy Ellingsen; Meredith E Pyle; Emily A Barron-Casella; James F Casella; Amanda B Payne; Jennifer Driggers; Heidi A Trau; Genyan Yang; Kimberly Jones; Solomon F Ofori-Acquah; W Craig Hooper; Michael R DeBaun Journal: Blood Date: 2012-09-10 Impact factor: 22.113
Authors: Jeffrey A Glassberg; Annie Chow; Juan Wisnivesky; Ronald Hoffman; Michael R Debaun; Lynne D Richardson Journal: Br J Haematol Date: 2012-09-12 Impact factor: 6.998
Authors: Michael R DeBaun; Mark Rodeghier; Robyn Cohen; Fenella J Kirkham; Carol L Rosen; Irene Roberts; Ben Cooper; Janet Stocks; Olu Wilkey; Baba Inusa; John O Warner; Robert C Strunk Journal: Am J Hematol Date: 2014-08-27 Impact factor: 10.047